| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $378,597 ) |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsins | 000 | 4 | NIH | 11/14/2024 | $263,805 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 000 | 2 | NIH | 11/15/2024 | $49,174 |
| | 2025 | 2025 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA279916 | Deiminated molecules as markers for developing pancreatic cancer - A1 | 000 | 2 | NIH | 11/15/2024 | $197,542 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 000 | 2 | NIH | 10/17/2024 | $0 |
| | 2025 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS136022 | Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (SEA-NOBI-ALS) | 000 | 1 | NIH | 10/10/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U24CA277825 | The Data, Evaluation, and Coordination Center (DECC) for Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) | 000 | 3 | NIH | 11/14/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA229560 | Role of ICAM1 in development and progression of pancreatic cancer | 000 | 5 | NIH | 11/6/2024 | $0 |
| | 2025 | 2023 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R24OD035424 | Implementation of automated staining in conjunction with spatial analyses | 000 | 1 | NIH | 10/28/2024 | $0 |
| | 2025 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA229811 | Predicting Breast Cancer Risk after Benign Percutaneous Biopsy | 000 | 5 | NIH | 11/5/2024 | -$6,396 |
| | 2025 | 2022 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA081436 | Protein Kinase C Signaling Mechanisms in Cancer | 000 | 25 | NIH | 11/5/2024 | -$53,444 |
| | 2025 | 2019 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1AG046205 | ApoE isoform-specific therapy for Alzheimer disease | 000 | 6 | NIH | 10/1/2024 | -$70,139 |
| | 2025 | 2019 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1NS085070 | Molecular mechanisms of PINK1-PRKN directed mitochondrial quality control | 000 | 6 | NIH | 10/1/2024 | -$1,944 |
|
| Issue Date FY: 2024 ( Subtotal = $59,642,564 ) (Continued on the next page) |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG054199 | APOE and microglia-mediated progression in tau pathology in AD | 000 | 3 | NIH | 7/12/2024 | $727,596 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA284153 | Evaluating the role of SPAK and OSR1 kinases in glioblastoma chemotherapy resistance | 001 | 1 | NIH | 7/12/2024 | $0 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG072719 | Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model | 000 | 4 | NIH | 4/26/2024 | $532,892 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21CA284153 | Evaluating the role of SPAK and OSR1 kinases in glioblastoma chemotherapy resistance | 000 | 1 | NIH | 7/8/2024 | $402,401 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG063780 | Mechanistic insights into the link between the A152T risk variant and tauopathy | 000 | 5 | NIH | 4/18/2024 | $402,502 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077656 | Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial | 002 | 2 | NIH | 6/6/2024 | $658,637 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01CA274970 | Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida | 004 | 4 | NIH | 9/5/2024 | $656,994 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG084236 | ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System | 003 | 2 | NIH | 9/11/2024 | $1,021,664 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG089380 | Bio-RaPID: Biomarkers and Rates of Progression In Dementia. | 000 | 1 | NIH | 9/6/2024 | $1,794,978 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA276313 | A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer | 000 | 2 | NIH | 6/12/2024 | $607,154 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and pathobiology of apoE in aging and Alzheimer's disease | 002 | 4 | NIH | 7/30/2024 | $0 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 002 | 1 | NIH | 4/30/2024 | $0 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG066429 | Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's disease | 001 | 5 | NIH | 6/28/2024 | $39,125 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG076537 | Extracellular vesicle-based senotherapeutics for aging diabetic kidneydisease | 001 | 2 | NIH | 6/28/2024 | $57,894 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG071513 | Investigating tau and ApoE4-mediated alterations in oligodendrocyte progenitor cells | 001 | 3 | NIH | 6/28/2024 | $63,148 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS118513 | Targeting Go and Grow in Glioblastoma | 000 | 5 | NIH | 7/12/2024 | $534,339 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R21NS128212 | GLIOMA INTERACTION WITH THE NEUROGENIC NICHE THROUGH EXTRACELLULAR VESICLES | 000 | 1 | NIH | 8/9/2024 | $430,375 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and pathobiology of apoE in aging and Alzheimer's disease | 001 | 4 | NIH | 7/15/2024 | $0 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG065219 | Impact of T cells on the CNS during aging and Alzheimer’s disease | 000 | 5 | NIH | 4/18/2024 | $485,150 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | P01NS084974 | Pathobiology of Neurodegeneration in C9ORF72 repeat expansion | 001 | 10 | NIH | 5/14/2024 | $0 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and pathobiology of apoE in aging and Alzheimer's disease | 000 | 4 | NIH | 6/5/2024 | $6,474,838 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 001 | 1 | NIH | 4/30/2024 | $1,280 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG067763 | Molecular characterization of extracellular vesicles for the spread of misfolded tau protein | 000 | 4 | NIH | 4/26/2024 | $611,392 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R37CA248298 | Role of Sirt2 in T Cell Metabolism | 002 | 5 | NIH | 4/18/2024 | $17,901 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS121125 | Frontotemporal dementia and related disorders: transcriptomic profiling, biomarker discovery, and mechanistic insight | 000 | 4 | NIH | 4/29/2024 | $780,935 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R13CA290996 | Science of Community Outreach and Engagement (SoCOE) Conference | 000 | 1 | NIH | 4/29/2024 | $10,000 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG066395 | TREM2-mediated microglial dynamic function in Alzheimer disease | 001 | 5 | NIH | 6/4/2024 | $74,211 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG066429 | Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's disease | 000 | 5 | NIH | 3/22/2024 | $352,125 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | P01NS084974 | Pathobiology of Neurodegeneration in C9ORF72 repeat expansion | 000 | 10 | NIH | 4/11/2024 | $2,581,235 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077771 | Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | 001 | 2 | NIH | 5/2/2024 | $69,376 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HL169268 | Individualized medicine to predict and prevent chemotherapy-related heart failure | 000 | 2 | NIH | 5/31/2024 | $632,207 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 001 | 3 | NIH | 5/2/2024 | $308,010 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 000 | 2 | NIH | 4/15/2024 | $8,291,222 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA262393 | Targeted Prevention of Postpartum-Related Breast Cancer (PRBC) | 001 | 3 | NIH | 4/16/2024 | $32,495 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01HL164520 | Role of mitochondrial extracellular vesicles in CVB3 myocarditis by sex | 000 | 3 | NIH | 6/27/2024 | $710,444 |
| | 2024 | 2024 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG071226 | Endothelial cell senescence and APOE4 in vascular cognitive impairment and dementia | 000 | 2 | NIH | 2/29/2024 | $352,125 |
|
